2003) Inhibition of food intake in obese subjects by peptide yy3-36
Concurrently, the Company is seeking to monetize its legacy nasal drug delivery business through licensing, partnering or acquisition of its Phase II intranasal programs, including its ultra rapid acting insulin for diabetes, Peptide YY3-36
for obesity and parathyroid hormone (PTH1-34) for osteoporosis.
The peer-reviewed paper, titled "Lower mean weight after 14 days intravenous administration peptide YY3-36
(PYY3-36) in rabbits," appears in the September 20, 2005, advanced online publication.
THIRD QUARTER 2004 CORPORATE HIGHLIGHTS Peptide YY3-36
Nasal Spray (PYY) for Obesity
The abstracts are: Quantitative Determination of Peptide YY3-36 in Plasma by Radioimmunoassay Foerder, C.
Nastech has developed and validated a radioimmunoassay method for the determination of Peptide YY3-36 (PYY), a satiety hormone, in plasma samples to support preclinical and clinical studies.
today announced that the Company has been selected to present data on the development of its first obesity formulation program, Peptide YY3-36
(PYY) Nasal Spray, at the 13th European Congress on Obesity, May 26-29, in Prague, Czech Republic.
a leader in drug delivery technology, announced today that it has commenced a Phase I clinical trial at Hammersmith Hospital, London, UK, to evaluate the intranasal administration of peptide YY3-36
(PYY) in the treatment of obesity.
a leader in drug delivery technology, today announced that the Company will present data on the development of its first obesity compound, an intranasal dosage form of Peptide YY3-36